$800 Million Investment Enhances Manufacturing Capabilities
BeiGene has proudly announced the grand opening of its state-of-the-art biologics manufacturing and clinical research and development (R&D) facility in Hopewell, New Jersey. This new establishment, constructed with an impressive investment of $800 million, showcases BeiGene’s commitment to meeting the growing demand for innovative cancer treatments.
Strategically Located for Global Impact
Situated within the Princeton West Innovation Campus, the facility spans 42 acres and is poised to become a pivotal site for the production of life-saving medicines for cancer patients around the world. The strategic location underscores BeiGene’s dedication to expanding its global reach and impact in the field of oncology.
Future-Focused with High-Tech Employment Opportunities
The facility is designed with the adaptability to scale production, addressing both current needs and future demands. This significant investment is the culmination of a three-year project aimed at bolstering BeiGene’s manufacturing and R&D footprint in the US. By the end of 2025, the Hopewell site is expected to create hundreds of high-tech job opportunities, further solidifying BeiGene’s role as a leader in the biopharmaceutical industry.
